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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not dasatinib
improves outcomes and tolerability in patients with chronic myeloid leukemia as compared to
imatinib.
Study Design: Review of three English language, non-blinded randomized controlled trials from
2009, 2010, and 2010.
Data Sources: Randomized, controlled, non-blinded clinical trials comparing dasatinib to
imatinib or comparing dasatinib once daily vs dasatinib twice daily, found using the PubMed
database.
Outcomes measured: Overall survival and progression-free survival were measured at one and
two years after initiation of therapy. Safety profiles and incidence of adverse effects were also
measured. This is graded on a scale of 1 to 4, from lowest in severity to highest in severity.
Additionally, adverse effects were noted as hematologic (neutropenia, anemia,
thrombocytopenia) or nonhematologic (fluid retention, diarrhea, vomiting, fever).
Results: When comparing dasatinib to imatinib, both drugs provided similar figures for
progression-free survival (96% vs 97% respectively) and overall survival (97% vs 99%
respectively). However, patients taking dasatinib progressed to accelerated or blastic phases of
CML 1.9% of the time, and those taking imatinib progressed 3.5% of the time. Dasatinib had
higher rates of hematologic adverse events, and imatinib had higher rates of nonhematologic
adverse events.
When comparing dasatinib 140 mg once daily to dasatinib 70 mg twice daily, the twice daily
dose produced higher overall survival at 12 months (84% vs 78%) and at 24 months (72% vs
63%), as well as fewer deaths due to progressive disease (43% vs 52%). Rates of
nonhematologic adverse events were similar between the two groups. However, the once daily
dose lead to lower incidence of gastrointestinal bleeding (8% vs 13%) and pleural effusion (20%
vs 39%).
Conclusions: Dasatinib improves outcomes and tolerability in patients with chronic myeloid
leukemia as compared to imatinib. This is advantageous not only considering patient quality of
life, but also morbidity and mortality from complications such as pleural effusions, congestive
heart failure, and bleeding. Additionally, by improving tolerability, patients are less likely to
discontinue treatment before completion of a full course of therapy.
Key Words: Chronic myeloid leukemia, dasatinib, imatinib
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INTRODUCTION
Chronic myeloid leukemia (CML) is a form of cancer originating in the bone marrow that
results in increased and unregulated growth of myeloid cells and their precursors.2 It is
associated with a characteristic translocation on the Philadelphia chromosome.2 Survival has
increased dramatically since the introduction of tyrosine kinase inhibitors (TKIs) such as
imatinib (brand name Gleevec) and dasatinib (brand name Sprycel).2
Imatinib, a first generation TKI, is the standard first-line therapy for patients with CML.3
Dasatinib, a second generation TKI, has been approved as second-line treatment for patients with
CML if imatinib therapy fails.3 In patients who fail or are unable to tolerate imatinib therapy,
dasatinib induces a complete cytogenic response approximately 50% of the time.3
This paper evaluates three randomized controlled trials comparing the effectiveness and
tolerability of imatinib and dasatinib.
Chronic myeloid leukemia has an incidence of 1-2 per 100,000 people, occurring most
commonly in middle-aged and elderly adults. This represents 15-20% of all adult leukemia.2
Ionizing radiation exposure, including radiation treatments used to treat other cancers, is the only
well-described risk factor for developing CML.2 In 2010, there were 4,870 newly diagnosed
cases of CML
Tyrosine kinase inhibitors are the gold standard for treatment of CML. Imatinib averages
$3170.40 for a 30 day supply, whereas Dasatinib averages $4676.40.3 While the cost is
significant, CML that is not treated with a TKI is associated with longer hospital stays and higher
morbidity.3
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CML is a bone marrow stem cell disorder that causes proliferation of mature
granulocytes (neutrophils, eosinophils, and basophils) and their precursors.2 Patients are often
asymptomatic at diagnosis, presenting incidentally with elevated white blood cell count on
routine complete blood count.2 Symptomatic patients may present with splenomegaly, malaise,
arthralgia, low-grade fever, immune compromise, anemia, and thrombocytopenia.2 A
characteristic genetic abnormality of CML is translocation on the Philadelphia chromosome
(translocation between chromosomes 9 and 22), resulting in BCR-ABL protein abnormalities.2
TKIs selectively inhibit the oncogene BCR-ABL, impeding the pathogenesis of CML.2
Imatinib is a first generation TKI that is proven to increase overall survival in CML.3
Dasatinib is a second generation TKI that may have higher overall survival in CML compared to
imatinib, as well as a more favorable safety profile.3
OBJECTIVE
The objective of this systematic review is to determine whether or not dasatinib improves
outcomes and tolerability in patients with chronic myeloid leukemia as compared to imatinib.
METHODS
All three randomized controlled trials utilized for this review were selected because their
population group included chronic myeloid leukemia patients greater than 18 years of age. Two
of the studies utilized patients who had shown resistance or intolerance to imatinib. In these
studies, one group of patients would receive dasatinib 140 mg once daily and the other group
would receive dasatinib 70 mg twice daily. One study focused on newly diagnosed patients with
CML. This study administered 100 mg of dasatinib once daily to one group of patients, with the
other receiving 400 mg of imatinib once daily.

Merusi; Dasatinib versus Imatinib in CML 3

The comparisons made in these studies were between imatinib and dasatinib. In the case
of the two studies utilizing different schedules of dasatinib, the comparison is between not only
imatinib and dasatinib (as these patients had received imatinib in the past), but also between
dasatinib 140 mg daily and dasatinib 70 mg twice daily. The outcomes measured in all three
trials were overall survival, progression-free survival, and safety profiles (adverse reactions to
therapy).
Information utilized in this review was found using the PubMed database. Inclusion
criteria included randomized controlled trials limited to the English language and published in
peer-reviewed journals. The key words used used in searches were: “chronic myeloid
leukemia”, “dasatinib”, and “imatinib”. Research was conducted by the author. Articles were
selected based on relevance to the clinical question and on the importance of outcomes to the
patient (POEMs). The inclusion criteria includes that the studies were randomized, controlled,
prospective, and included patient oriented outcomes (POEMs). Exclusion criteria included trials
with patients under the age of 18 and studies that focused exclusively on disease oriented
outcomes (DOEs). Ultimately, three studies were found and analyzed. They included: 1) a
randomized, open-label, multinational phase 3 trial comparing dasatinib 100 mg daily and
imatinib 400 mg daily in patients with newly diagnosed CML, 2) a randomized, 2-arm,
multicenter, open-label, phase 3 trial comparing dasatinib140 mg daily and dasatinib 70 mg
twice daily in patients with CML who had proven to be imatinib resistant or imatinib intolerant,
and 3) a randomized, multicenter, open-label, phase 3 trial comparing dasatinib 140 mg daily and
dasatinib 70 mg twice daily in patients with CML who had proven to be imatinib resistant or
imatinib intolerant. A summary of the statistics used include: p-values, RRR, ARR, NNT, NNH.
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Table 1: Demographics of included studies
Study

Number
of
patients
Randomized, 317
2-arm, Phase
3 trial

Age

Inclusion
Criteria

Exclusion Criteria

W/D Interventions

18+

Treatment with
imatinib, within 7
days of initiation,
uncontrolled or
significant
cardiovascular
disease, history of
a significant
bleeding disorder
unrelated to CML,
any other
concurrent
malignancy other
than CML

206

Randomized
to receive
dasatanib
140 mg QD
or dasatinib
70 mg BID

Kantarjian
20103

Randomized, 519
Phase 3 trial

18+

Patients
stopped
treatment
with imatinib
due to
resistance or
intolerance,
Eastern
Cooperative
Oncology
Group
(ECOG)
performance
status score of
0-2, adequate
hepatic/renal
function
Chronic CML
diagnosed by
means of
bone marrow
biopsy within
3 months of
study, no
previous
treatments for
CML, ECOG
performance
status score of
0-2 and
adequate
hepatic and
renal function

90

Randomized
to receive
dasatinib
100mg QD
or imatinib
400mg QD

Saglio
20104

Randomized, 210
Phase 3 trial

16 78

198

Randomized
to receive
dasatanib
140 mg QD
or dasatinib
70 mg BID

Kantarjian
20091

Type

Women who were
breastfeeding/pregnant/
could potentially
become pregnant,
serious
comorbidities,
active infections,
serious
cardiovascular
disease, history of
a significant
bleeding disorder
unrelated to CML,
concurrent
malignancy other
than CML
Resistance or Serious
intolerance to comorbidities,
imatinib
active infections,
previously, no serious
previous
cardiovascular
treatments for disease, history of
CML, ECOG a significant
score of 0-2,
bleeding disorder
adequate
unrelated to CML,
hepatic/renal
concurrent
function
malignancy other
than CML
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RESULTS
The results were presented in dichotomous form in all three studies analyzed. In the
Kantarjian et al 2010 study, the rate of complete cytogenic response by 12 months was
significantly greater among patients receiving dasatinib than those treated with imatinib (77%
versus 66%, P=0.007). Progression to the accelerated or blastic phase of CML occurred in 1.9%
of patients receiving dasatinib, compared to 3.5% of those receiving imatinib. At 12 months, the
rates of progression-free survival were similar for patients receiving dasatinib versus imatinib
(96% vs 97%). The rates of overall survival were also similar for patients receiving dasatinib
versus imatinib (97% and 99%).
Table 2: Efficacy of Dasatinib versus Imatinib in patients with CML

Dasatinib
Imatinib

Progression to
accelerated or blastic
phase of CML
1.9%
3.5%

Progression-free
survival (at 12
months)
96%
97%

Overall survival (at 12
months)
97%
99%

The safety profiles revealed greater differences in patient responses to the two drugs. As
noted in Table 3, dasatinib had higher rates of hematologic adverse events (neutropenia,
thrombocytopenia, and anemia). However, imatinib had higher rates of nonhematologic adverse
events (fluid retention, diarrhea, nausea, etc.). The overall rates of discontinuation of therapy
because of toxic drug effects were 5% with dasatinib and 4% with imatinib. There was one
death in each group that was attributed to study treatment, both the result of myocardial
infarction.
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Table 3: Adverse events associated with Dasatinib and Imatinib
Neutropenia Thrombocytopenia Anemia
Dasatinib
Imatinib

65%
58%

70%
62%

90%
84%

Fluid
retention
19%
42%

Diarrhea

Vomiting

17%
17%

5%
10%

In the Saglio et al study, dasatinib 140 mg daily is compared to dasatinib 70 mg twice
daily in patients who have already failed imatinib therapy. The median progression-free survival
is for the once daily arm and twice daily arm is 3.8 months and 3.7 months respectively.
However, the 24 month progression-free survival rate was 11% for the once daily regimen and
18% for the twice daily regimen. The median overall survival was also similar, with 7.9 months
in the one daily arm and 7.7 months in the twice daily arm. The 24 month overall survival rates
were 24% in the once daily arm and 28% in the twice daily arm. The majority of deaths were
considered to be from CML, with 54% in the once daily arm and 41% in the twice daily arm.
Table 4: Efficacy of Dasatinib 140 mg daily versus Dasatinib 70 mg twice daily in patients with
imatinib-resistant or intolerant CML
Dasatinib 140
mg daily
Dasatinib 70 mg
twice daily

Median PFS
3.8 months

PFS Rate
11%

Median OS
7.9 months

OS Rate
24%

3.7 months

18%

7.7 months

28%

The more common adverse events were fluid retention, diarrhea, headache, bleeding,
nausea, fatigue, and rash, and these were typically mild (Grade 1 or 2). The rates were similar in
both arms. Cytopenias also had a similar incidence in both arms.
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Table 5: Cytopenias associated with Dasatinib 140 mg QD compared to Dasatinib 70 mg BID
Dasatinib 140
mg QD
Dasatinib 70 mg
BID

Neutropenia
65/72 (90%)

Thrombocytopenia Anemia
67/72 (93%)
70/72 (97%)

Leukocytopenia
60/72 (83%)

65/73 (89%)

67/73 (92%)

61/71 (84%)

73/73 (100%)

In the Katarjian et all 2009 study, dasatinib 140 daily was compared to dasatinib 70 mg
twice daily in patients with accelerated phase resistant CML or patients intolerant to imatinib.
The overall survival rates were 78% (95% CI, 71-84%) and 84% (95% CI, 65-79%) for the once
daily and twice daily groups respectively at 12 months. At 24 months, the rates were 63% (95%
CI, 56-71%) for once daily and 72% (95% CI, 65-79%) for twice daily (P=.140). Among
patients who died during the study, a similar number died of progressive disease in each of the
two treatment groups (52% for the once daily group, 43% for the twice daily group; P=.435).
Table 6: Overall survival rates with Dasatinib 140 mg QD compared to Dasatinib 70 mg BID

Dasatinib 140 mg QD
Dasatinib 70 mg BID

OS at 12 months

OS at 24 months

78%
84%

63%
72%

Deaths due to
progressive disease
(among total deaths)
52%
43%

Both dasatinib schedules were relatively well tolerated during the study, with a majority
of adverse events being mild or moderate (Grades 1 or 2). The rates of non-hematologic adverse
events were similar between the two groups, though there was a lower incidence of
gastrointestinal bleeding seen with the once daily group compared to the twice daily group (8%
versus 13% respectively, P=.2036). Pleural effusion rates were also lower in the once daily
group (20% once daily versus 39% twice daily, P <.001). The rates of congestive heart failure or
other cardiac dysfunction were 0% in the once daily group and 3% in the twice daily group. The
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most common non-hematologic adverse events included diarrhea, fluid retention, nausea,
headache, and fatigue. Incidences of all-grade cytopenia were high and comparable in both
groups.
DISCUSSION
The randomized controlled trial comparing dasatinib to imatinib in newly diagnosed
patients with CML showed that with either drug, survival rates are extremely high. However,
dasatinib proved to prevent progression to the more severe blastic phase of CML significantly
better than imatinib. With dasatinib therapy, progression rates we reduced by about half. When
comparing safety profiles, the two drugs had similarly high rates of cytopenias. Tyrosine kinase
inhibitors (such as imatinib and dasatinib) prevent ATP binding to BCR-ABL gene expressing
cells, leading to selective growth disadvantage or apoptotic death of those cells. Because of this,
hematologic cell growth is expected to be diminished to some degree. However, dasatinib had a
significantly lower rate of non-hematologic adverse events. The rates of fluid retention are more
than halved when using dasatinib rather than imatinib, which not only increases quality of life
but also decreases potentially deadly complications such as congestive heart failure and pleural
effusion. There was also a significant decrease in constitutional symptoms such as myalgia,
vomiting, and diarrhea.
The second two randomized controlled trials compared dasatinib 140 mg once daily to
dasatinib 70 mg twice daily. This patient population was different than in the first study
analyzed because they had already discontinued imatinib therapy due to failure of therapy or
intolerability of adverse effects. These patients tended to have more progressive disease, and
therefore, higher morbidity and mortality.

Merusi; Dasatinib versus Imatinib in CML 9

In both studies that compared the two dose schedules, efficacy was quite similar. This
was noted in both progression-free survival and overall survival. However, the once daily
regimen had improved tolerability. This is significant when considering both quality of life and
potential complications in patients treated with dasatinib. Once daily scheduling showed
decreased incidences of fluid retention (manifesting itself as superficial edema, pleural effusion,
pericardial effusion, and congestive heart failure) as well as gastrointestinal bleeding. These are
significant sources of morbidity and mortality amongst patients with CML.
There were a few limitations to these studies. The two studies involving dasatinib dosed
daily or twice daily only focused on patients who had already failed imatinib therapy. It is not
known which dose schedule would be more effective or tolerable in a newly diagnosed patient.
These studies were also not blinded. Large numbers of patients withdrew from these studies for
a multitude of reasons, including disease improvement, intolerability to therapy, disease
progression, and death.
CONCLUSION
Overall, dasatinib does improve outcomes and tolerability in patients with chronic
myeloid leukemia as compared to imatinib. While overall survival is similar between the two
drugs, progression-free survival is significantly improved with dasatinib. There is also a
substantial improvement in tolerability when using dasatinib. This is advantageous not only
considering patient quality of life, but also morbidity and mortality from complications such as
pleural effusion, congestive heart failure, and bleeding. Additionally, many patients discontinue
imatinib before completing a full course of therapy. By improving tolerability, patients are more
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likely to complete the prescribed treatment regimen and, therefore, will receive the maximum
response.
Currently, treatment with dasatinib is only indicated after imatinib therapy has failed.
The first generation ABL-BCR tyrosine kinase inhibitor is still considered first line therapy, with
second generation TKIs such as dasatinib being second line therapy. In the future, it may be
beneficial to study dasatinib as first line therapy in newly diagnosed CML. This would allow
researchers to determine the response to dasatinib in patients who have less progressive disease
and have not already been exposed to other cytotoxic therapies.
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